Key Stats for Eli Lilly Stock
- Current Price: $1,257.03
- Target Price (Mid): ~$2,216
- Street Target: ~$1,328
- Potential Total Return: ~76%
- Annualized IRR: ~14% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Eli Lilly and Company (LLY) moved a step closer to selling its Foundayo weight-loss pill in the European Union on October 16. That day, the European Medicines Agency announced that its human medicines committee recommends approval. The stock rose 0.43% to close at $1,257.03, 1.82% below its August 19 record close of $1,280.34.
The bigger gains came on October 14 and 15, when shares rose 3.62% and 3.55%. The first came the day a hotter-than-expected inflation report weighed on U.S. indices, and no single Lilly-specific catalyst explains either session. Lilly’s investor relations materials hold the trial data behind the EU filing.
See historical and forward estimates for Eli Lilly stock (It’s free!) >>>
Novo Reached the EU First, and Most Markets Outside the U.S. Pay Cash
The committee adopted its opinion on October 15 for weight management and type 2 diabetes in adults. It is a recommendation, not an approval; the European Commission makes the final decision. Novo Nordisk (NVO) won EU approval for its Wegovy pill in July, and Foundayo has been sold in the U.K. since August.
At a Morgan Stanley conference on September 14, Ilya Yuffa, Executive Vice President and President of Lilly USA and Global Customer Capabilities, said around 75% of the market outside the U.S. is self-pay. He noted Lilly had recently won obesity reimbursement in France. Outside the U.S., Foundayo’s growth is likely to come from volume before pricing.
Foundayo Is Winning Starts Faster Than Revenue
Lilly reported $98 million of Foundayo sales in Q2 2026, under 0.5% of its $22.97 billion in total revenue. Novo reported DKK 3.22 billion of Wegovy pill sales in the same quarter, from a pill that launched in January, about three months before Foundayo.
Yuffa pointed to the mix. Most Foundayo starts are self-pay, and “those are at lower price points initially until people get through to higher doses.” By September 14, he said Foundayo held “more than 30% share in new starts within oral GLP-1,” a marked improvement over the prior two months. Revenue per patient rises only if those patients stay long enough to step up, and he said early second-fill data “is very good.”
The valuation leaves little room for that ramp to stall. Lilly trades at around 32x NTM P/E, against around 12x for Novo and around 18x for Merck (MRK), per TIKR.
See how Eli Lilly performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $1,257.03
- Target Price (Mid): ~$2,216
- Potential Total Return: ~76%
- Annualized IRR: ~14% / year
See analysts’ growth forecasts and price targets for Eli Lilly stock (It’s free!) >>>
Using the mid case, the model’s central scenario, TIKR targets around $2,216 by December 31, 2030. That is a total return of around 76%, or around 14% a year, over about 4.2 years. Separately, consensus compiled by TIKR sees revenue rising from $65.18 billion in 2025 to around $134 billion in 2030, with normalized net margin near 44%. Only 17 analysts estimate 2030 revenue.
The Street’s mean target of around $1,328 sits about 6% above the October 16 close. Ratings stand at 20 Buy, 6 Outperform, 3 Hold, 1 Underperform, 1 Sell, and 2 No Opinion.
The primary risk is that Foundayo patients stall on starter doses or stop before stepping up. Upside comes if cash-pay markets outside the U.S. convert to higher doses as the U.S. launch matures. The downside comes if Novo’s earlier start locks in pill patients before Foundayo reaches EU pharmacies.
Conclusion
Q3 is Foundayo’s first full quarter with Medicare’s GLP-1 Bridge program, which began July 1, and with Lilly’s expanded consumer advertising. On October 29, compare Foundayo revenue with Q2’s $98 million, against any prescription growth Lilly discloses. Revenue growing faster than prescriptions would mean patients are moving to higher doses. Revenue that merely tracks prescriptions would mean most are still paying starter prices.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
So what is Eli Lilly stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what Eli Lilly could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Analyze Eli Lilly on TIKR Free →
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
